A Phase 2 interventional study of Long-term Dosing Cohort and Single ascending doses of MT1013 in Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis, sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Hyperparathyroidism, Secondary with a site in China — 4 open to participants now, 5 under way, 1 of them phase 3. Hyperparathyroidism, Secondary · China.
Among the 23 studies in Hyperparathyroidism, Secondary with a site in China, this one is the 11th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2023, is one of 5 in phase 2, and was the 18th registered.
188 studies on the registry are indexed under Hyperparathyroidism, Secondary; 15 are open to participants now.
Browse Hyperparathyroidism, Secondary studies →4 of the 23 studies in Hyperparathyroidism, Secondary with a site in China are open now. Recruiting first, the newest first:
Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 18+
Shaanxi Micot Technology Limited Company · Sites in China
Ages 18+
The Second Hospital of Nanjing Medical University · Sites in China
Ages 18–70
Limeng Chen · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2023.
This study's enrollment of 98 is above the median of 62 across 146 interventional studies indexed under Hyperparathyroidism, Secondary.
Median enrollment 158 across the 18 interventional studies, 192 across the 5 observational. Of the 14 that completed or were terminated, 3 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 23 have an industry lead sponsor. The 10 most frequent:
Shaanxi Micot Pharmaceutical Technology Co., Ltd. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Shaanxi Micot Pharmaceutical Technology Co., Ltd. has 4 studies filed under Hyperparathyroidism, Secondary — fewer than ten, so there is no comparison to draw.
1 of the studies in Hyperparathyroidism, Secondary with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07122401Phase 3Shaanxi Micot Pharmaceutical Technology Co., Ltd.Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism | 2026-11-26 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Hyperparathyroidism, Secondary with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A multicenter, Phase II, randomized, double-blind, single ascending dose (SAD) and multiple ascending dose (MAD), as well as single-arm clinical study evaluating the long-term efficacy and safety of MT1013 in hemodialysis subjects with secondary hyperparathyroidism. The SAD study consists of five cohorts at doses of 5, 10, 20, 40, and 60 mg. The MAD study consists of three cohorts at doses of 5, 10, and 20 mg. In both the SAD and MAD studies, each cohort includes 8 subjects (6 subjects receive the active investigational drug, and 2 subjects receive matching placebo), and the cohorts are conducted sequentially. In the long-term dosing cohort, all subjects will undergo regular hemodialysis three times per week, receiving the drug once after each hemodialysis session for a total duration of 52 weeks
Inclusion Criteria (Subjects must meet all of the following criteria to participate in the trial):
Postmenopausal is defined as:
Age ≥55 years \& amenorrhea for ≥12 months;
Or Age \<55 years but no spontaneous menses for at least 2 years;
Or Age \<55 years with spontaneous menses within the past 1 year, but currently amenorrheic, and with postmenopausal gonadotropin levels (luteinizing hormone and follicle-stimulating hormone levels >40 IU/L) or postmenopausal estradiol levels (\<5.3 pmol/L or 5 ng/dL) or meeting the laboratory's definition of "postmenopausal range";Having undergone bilateral oophorectomy.
Exclusion Criteria (Subjects meeting any of the following criteria will be excluded from the study):
1 .History of severe ventricular arrhythmia or symptomatic ventricular arrhythmia at screening, or >470 ms for males or >480 ms for females at screening;
2. Subjects with heart failure symptoms,class III or IV by (NYHA) , at screening;
3. History of myocardial infarction, coronary angioplasty, or coronary artery bypass graft within the past 6 months;
4. History of seizures or having received treatment for seizures;
5. Prior parathyroidectomy;
6. Serum transaminases (, aspartate aminotransferase) >3 times the at screening; or serum albumin \<30 g/L;
7.History of organ transplant (excluding being on the kidney transplant waiting list), hematopoietic stem cell transplant, or bone marrow transplant; or patients planning to undergo organ transplantation;
8.Severe uncontrolled hypertension, defined as systolic blood pressure >180 mmHg and diastolic blood pressure >100 mmHg despite optimal medical therapy before enrollment;
9.Known or other comorbidities with a of \<3 months (except for patients disease-free for ≥5 years, or disease-free for ≥5 years after the last dose of chemotherapy );
10.Known alcohol or illicit drug abuse within 12 months prior to screening, unwillingness or inability to abstain from alcohol for 24 hours prior to each study visit, or unwillingness or inability to limit alcohol consumption to a maximum of 2 drinks per day during the study (one drink is equivalent to 360 mL of regular beer, 150 mL of wine, or 45 mL of 40% alcohol spirits);
11.Positive for (HIV) or known diagnosis of acquired immunodeficiency syndrome (AIDS) at screening;
12.Subjects positive for surface antigen (HBsAg) at screening (indicative of chronic hepatitis B) AND with serum transaminases (alanine aminotransferase, aspartate aminotransferase) >2 times the upper limit of normal;
13.Positive for virus ribonucleic acid (RNA) by polymerase chain reaction (PCR) at screening (indicative of active hepatitis C - usually screened via hepatitis C antibody [HCV-Ab], with PCR for HCV RNA if HCV-Ab positive);
14.Patients with known to the product and/or its components;
15.Patients who have participated in another clinical trial and received an investigational drug within 8 weeks prior to the first dose or within 5 half-lives of the investigational drug (whichever is longer);
16. Patients who have previously received MT1013;
17. Subjects who have received cinacalcet treatment within 8 days prior to the first dose;
18. Pregnant or potentially pregnant women or lactating women;
19. Inability to fully comply with the study protocol;
20.Any other medical or psychiatric condition that, in the investigator's opinion, precludes participation in the study;
21. Subjects with active gastrointestinal bleeding or a high risk of astrointestinal bleeding tendency at screening.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single ascending doses of MT1013
Drug: Single ascending doses of MT1013
Placebo comparator for SAD
Drug: Single ascending doses of MT1013
Multiple ascending doses of MT1013
Drug: Multiple ascending doses of MT1013
Placebo comparator for MAD
Drug: Multiple ascending doses of MT1013
Dose titration period covers the first 10 weeks , followed by maintenance dosing period, for a total treatment duration of 52 weeks
Drug: Long-term Dosing Cohort
All subjects will undergo regular hemodialysis three times per week. Administration of MT1013occurs once after each hemodialysis session and will continue for 52 weeks. The first 10 weeks constitute the dose-titration period, during which the drug dose is titrated every 3 weeks based on iPTH and serum corrected calcium levels. During the maintenance dosing period, doses is adjusted based on iPTH and serum corrected calcium levels.
All subjects will receive a single dose (MT1013 or placebo) only after a single hemodialysis session
All subjects will undergo hemodialysis three times per week. Dosing (MT1013 or placebo) will occur once after each hemodialysis session, continuing for either 2 or 4 weeks (treatment period).
SAD/MAD :Percentage of treatment-emergent adverse events (TEAEs)
To investigate the safety and tolerability of MT1013 by assessing the incidence and severity of TEAEs in Single Ascending Dose (SAD Cohort) and Multiple Ascending Doses (MAD Cohort)
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2
Long-term Dosing Cohort: Proportion of subjects with > 30% reduction in serum iPTH compared to baseline level.
Proportion of subjects achieving a \>30% reduction in serum iPTH from baseline at Week 14.
Time frame: 14 weeks
Change in the mean serum intact parathyroid hormone (iPTH) from baseline
Change in serum intact parathyroid hormone (iPTH) from baseline at each visit
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2. Long-term Dosing Cohort: 52 weeks
Proportion of subjects achieving a >30% reduction in serum iPTH from baseline
Proportion of subjects achieving a \>30% reduction in serum iPTH from baseline at each visit
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2. Long-term Dosing Cohort: 52 weeks
Change from baseline in corrected Ca
Change in corrected calcium from baseline at each visit
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2. Long-term Dosing Cohort: 52 weeks
Change from baseline in ionized calcium
Change in ionized calcium from baseline at each visit
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2
Change in DXA-measured bone mineral density (BMD) at the femoral neck and lumbar spine from baseline
Change in DXA-measured bone mineral density (BMD) at the femoral neck and lumbar spine from baseline at each visit
Time frame: Long-term Dosing Cohort: 52 weeks
Incidence and severity of treatment-emergent adverse events (TEAEs)
Incidence and severity of adverse events occurred during the study period
Time frame: Long-term Dosing Cohort: 52 weeks
Change from baseline in serum phosphorus
Change in serum phosphorus from baseline at each visit
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2
Change from baseline in the mean corrected calcium-phosphorus product
Change in the mean corrected calcium-phosphorus product from baseline at each visit
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2
Assessment change of Bone Turnover Markers - Change from Baseline
Change in PINP from baseline at each visit
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2. Long-term Dosing Cohort: 52 weeks
Assessment change of Bone Turnover Markers - Change from Baseline
Change in CTX from baseline at each visit
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2. Long-term Dosing Cohort: 52 weeks
Assessment change of Bone Turnover Markers - Change from Baseline
Change in OC from baseline at each visit
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2. Long-term Dosing Cohort: 52 weeks
Assessment change of Bone Turnover Markers - Change from Baseline
Change in b-ALP from baseline at each visit
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2. Long-term Dosing Cohort: 52 weeks
Assessment change of Bone Turnover Markers - Change from Baseline
Change in TRAP-5b from baseline at each visit
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2. Long-term Dosing Cohort: 52 weeks
Cmax of MT1013
Cmax - Maximum plasma concentration
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2
Tmax of MT1013
Tmax - Time to reach Cmax
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2
T1/2 of MT1013
T1/2 - Elimination half-life
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2
AUC0-tau of MT1013
AUC0-tau - Area under the plasma concentration-time curve during one dosing interval
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2
AUC0-t of MT1013
AUC0-t - Area under the plasma concentration-time curve from time zero to the last measurable concentration
Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2
Ran from Apr 2023 to primary completion in May 2025, 25 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyperparathyroidism, Secondary →
Shaanxi Micot Pharmaceutical Technology Co., Ltd.